期刊文献+

过敏性紫癜患者血浆TM、vWF和P-选择素水平的研究 被引量:1

下载PDF
导出
摘要 研究血浆凝血酶调节蛋白(thronmbomodulin TM)、血管假性血友病因子(von Willebrand factor vWF)和P-选择素在过敏性紫癜(ALP)发病机制中的作用。方法:采用ELISA法检测儿童过敏性紫癜患者血浆TM,vWF和P-选择素水平。结果:单纯型过敏性紫癜、合并肾脏损伤的过敏性紫癜患儿血浆TM,vWF和P-选择素水平均明显高于对照组(P〈0.05);合并肾脏损伤的过敏性紫癜患儿血浆TM,vWF水平明显高于单纯型过敏性紫癜(P〈0.05);单纯型过敏性紫癜患儿血浆P-选择素水平与合并肾脏损伤的过敏性紫癜患儿之间比较无统计学意义(P〉0.05)。
出处 《中国麻风皮肤病杂志》 2008年第12期974-975,共2页 China Journal of Leprosy and Skin Diseases
基金 河北省科技厅支撑计划项目(072761554)
  • 相关文献

参考文献5

二级参考文献7

  • 1王振义 李家增 等.血栓与止血基础理论与临床(第二版)[M].北京:上海科学技术出版社,1995.531-533.
  • 2吴国新,Clin Med J (Engl),1992年,105卷,553页
  • 3吴国新,Nouv Rev Fr Hematol,1992年,34卷,31页
  • 4吴国新,Thromb Haemostas,1991年,65卷,1193页
  • 5吴国新,Nouv Rev Fr Hematol,1990年,32卷,231页
  • 6吴国新,Haemostasis,1993年,23卷,121页
  • 7王振义,血栓与止血.基础理论与临床(第2版),1995年,531页

共引文献1769

同被引文献14

  • 1Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. TheCommittee on Prognosis Studies in SLE . Arthritis Rheum, 1992, 35 : 635-640.
  • 2Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med, 1983, 75: 382-391.
  • 3Lenting PJ, Pegon JN, Groot E, et al. Regulation of von WiUe- brand factor-platelet interactions. Thromb Haemost, 2010, 104 : 449-455.
  • 4Ware LB, Eisner MD, Taylor Thompson B, et al. Significance of yon Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med, 2004, 170: 766-772.
  • 5Hansen RR, Tipnis AA, White-Adams TC. et al. Characteriza- tion of collagen thin films for yon Willebrand factor binding and platelet adhesion. Langmuir, 2011, 27 : 13648-13658.
  • 6Rieger M, Mannucci PM, Kremer-Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106: 1262-1267.
  • 7Mannucci PM, Vanoli M, Forza I, et al. Von Willebrand factor- cleaving protease (ADAMTS1 3) in 123 patients with connective tissue disease (systemic lupus erythematosus and systemic scle- rosis). Haematologica (Pavia), 2003, 88: 914-918.
  • 8Plccin A, Murphy WG, Smith OP. Circulating microparticles: Pathophysiology and clinical implications. Blood Rev, 2007, 21 : 157-171.
  • 9Varughese GI, Patel JV, Tomson J, et al. Prognostic value of plasma soluble P-selectin and yon Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in highrisk patients with hypertension: a sub-study of the Anglo-Scandi-na- vian Cardiac Outcomes Trial. J Intern Med, 2007, 261: 384-391.
  • 10Morris DL, Graham RR, Erwig LP.Variation in the upstream region of P-Selectin is a risk factor for SLE. Genes Immun, 2009, 10: 404-413.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部